Cyclin D1 and PSA act as good prognostic and clinicopathological indicators for breast cancer

References

• New Global Cancer Data: GLOBOCAN 12 September 2018.
   Google Scholar
• Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global Cancer Statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. DOI: 10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Ibrahim, A. S.; Khaled, H. M.; Mikhail, N. N.; Baraka, H.; Kamel, H. Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J. Cancer Epidemiol. 2014, 2014, 437971. DOI: 10.1155/2014/437971.
   PubMedGoogle Scholar
• El Bolkainy, M. N.; Nouh, M. A.; Farahat, I. G.; El Bolkainy, T. N.; Badawy, O. M. Breast Cancer, in Pathology of Cancer, 5th ed. 2016. Chapter 18; pp. 298–312
   Google Scholar
• Lee, A.; Park, W. C.; Yim, H. W.; Lee, M. A.; Park, G.; Lee, K. Y. Expression of c-erbB2, Cyclin D1 and Estrogen Receptor and Their Clinical Implications in the Invasive Ductal Carcinoma of the Breast. Jpn. J. Clin. Oncol. 2007, 37, 708–714. DOI: 10.1093/jjco/hym082.
   PubMed Web of Science ®Google Scholar
• Ravikumar, G.;. Ananthamurthy, A. Cyclin D1 Expression in Ductal Carcinoma of the Breast and Its Correlation with Other Prognostic Parameters. J. Can. Res. Ther. 2014, 10, 671–675.
   PubMed Web of Science ®Google Scholar
• Comstock, C. E.; Augello, M. A.; Schiewer, M. J.; Karch, J.; Burd, C. J.; Ertel, A.; Knudsen, E. S.; Jessen, W. J.; Aronow, B. J.; Knudsen, K. E. Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function. J. Biol. Chem. 2011, 286, 8117–8127. DOI: 10.1074/jbc.M110.170720.
   PubMed Web of Science ®Google Scholar
• Turner, B. C.; Gumbs, A. A.; Carter, D.; Glazer, P. M.; Haffty, B. G. Cyclin D1 Expression and Early Breast Cancer Recurrence following Lumpectomy and Radiation. Int. J. Radiat. Oncol. 2000, 47(5), 1169–1176. DOI: 10.1016/S0360-3016(00)00525-3.
   PubMed Web of Science ®Google Scholar
• Narita, D.; Anghel, A.; Motoc, M. Prostate-specific Antigen May Serve as a Pathological Predictor in Breast Cancer. Rom. J. Morphol. Embryol. 2008, 49(2), 173–180.
   PubMed Web of Science ®Google Scholar
• Sauter, E. R.; Klein, G.; Wagner-Mann, C.; Diamandis, E. P. Prostate-specific Antigen Expression in Nipple Aspirate Fluid Is Associated with Advanced Breast Cancer. Cancer Detect. Prev. 2004, 28(1), 27–31. DOI: 10.1016/j.cdp.2003.11.003.
   PubMedGoogle Scholar
• Edge, S. B.; Byrd, D. R.; Compton, C. C.; Fritz, A. G.; Greene, F. L.; Trotti, A. AJCC Cancer Staging Manual, 7th ed.; Springer-Verlag: New York, NY, 2010.
   Google Scholar
• Goldhirsch, A.; Wood, W. C.; Coates, A. S.; Gelber, R. D.; Thurlimann, B.; Senn, H. J. Panel MStrategies for Subtypes-dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann. Oncol. 2011, 22, 1736–1747. DOI: 10.1093/annonc/mdr304.
   PubMed Web of Science ®Google Scholar
• Ortiz, A. B.; Garcia, D.; Vicente, Y.; Palka, M.; Bellas, C.; Martin, P. Prognostic Significance of Cyclin D1 Protein Expression and Gene Amplification in Invasive Breast Carcinoma. PLoS ONE. 2017, 12(11). DOI: 10.1371/journal.pone.0188068.
   Web of Science ®Google Scholar
• Khoo, M. L. C.; Beasley, N. J. P.; Ezzat, S.; Freeman, J. L.; Asa, S. L. Overexpression of Cyclin D1 and Underexpression of P27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 2002, 87, 1814–1818. DOI: 10.1210/jcem.87.4.8353.
   PubMed Web of Science ®Google Scholar
• Moinfar, F.; Okcu, M.; Tsybrovskyy, O.; Regitnig, P.; Lax, S.; Weybora, W.; Ratschek, M.; Tavassoli, F. A.; Denk, H. Androgen Receptors Frequently are Expressed in Breast Carcinomas: Potential Relevance to New Therapeutic Strategie. Cancer. 2003, 98(4), 703–711. DOI: 10.1002/cncr.11532.
   PubMed Web of Science ®Google Scholar
• Dawson, B.; Trapp, R. Basic and Clinical Biostatistics: Large Medical Books; Oxford: London, Boston, 2001.
   Google Scholar
• Arnold, A.; Papanikolaou, A. Cyclin D1 in Breast Cancer Pathogenesis. J. Clin. Oncol. 2005, 23, 4215–4224. DOI: 10.1200/JCO.2005.05.064.
   PubMed Web of Science ®Google Scholar
• Roy, P. G.; Thompson, A. M. Cyclin D1 and Breast Cancer. Breast. 2006, 15, 718–727. DOI: 10.1016/j.breast.2006.02.005.
   PubMed Web of Science ®Google Scholar
• Hwang, T. S.; Han, H. S.; Hong, Y. C.; Lee, H. J.; Paik, N. S. Prognostic Value of Combined Analysis of Cyclin D1 and Estrogen Receptor Status in Breast Cancer Patients. Pathol. Int. 2003, 53, 74–80. DOI: 10.1046/j.1440-1827.2003.01441.x.
   PubMed Web of Science ®Google Scholar
• Peurala, E.; Koivunen, P.; Haapasaari, K. M.; Bloigu, R.; Jukkola-Vuorinen, A. The Prognostic Significance and Value of Cyclin D1, CDK4 and P16 in Human Breast Cancer. Breast Cancer Res. 2013, 15, R5. DOI: 10.1186/bcr3376.
   PubMed Web of Science ®Google Scholar
• Chung, J.; Noh, H.; Park, K. H.; Choi, E.; Han, A. Longer Survival in Patients with Breast Cancer with Cyclin D1 Over-expression after Tumor Recurrence: Longer, but Occupied with Disease. J. Breast Cancer. 2014, 17, 47–53. DOI: 10.4048/jbc.2014.17.1.47.
   PubMed Web of Science ®Google Scholar
• Mylona, E.; Tzelepis, K.; Theohari, I.; Giannopoulou, I.; Papadimitriou, C.; Nakopoulou, L. Cyclin D1 in Invasive Breast Carcinoma: Favourable Prognostic Significance in Unselected Patients and within Subgroups with an Aggressive Phenotype. Histopathology. 2013, 62, 472–480. DOI: 10.1111/his.12013.
   PubMed Web of Science ®Google Scholar
• Han, E. K.; Sgambato, A.; Jiang, W.; Zhang, Y. J.; Santella, R. M.; Doki, Y. Stable Overexpression of Cyclin D1 in a Human Mammary Epithelial Cell Line Prolongs the S-phase and Inhibits Growth. Oncogene. 1995, 10, 953–961.
   PubMed Web of Science ®Google Scholar
• Yu, Q.; Geng, Y.; Sicinski, P. Specific Protection against Breast Cancers by Cyclin D1 Ablation. Nature. 2001, 411, 1017–1021. DOI: 10.1038/35082500.
   PubMed Web of Science ®Google Scholar
• Sutherland, R. L.; Musgrove, E. A. Cyclin D1 and Mammary Carcinoma: New Insights from Transgenic Mouse Models. Breast Cancer Res. 2002, 4, 14–17.
   PubMed Web of Science ®Google Scholar
• Kenny, F. S.; Hui, R.; Musgrove, E. A.; Gee, J. M.; Blamey, R. W.; Nicholson, R. I. Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer. Clin. Cancer. Res. 1999, 5, 2069–2076.
   PubMed Web of Science ®Google Scholar
• Han, E. K.; Sgambato, A.; Jiang, W.; Zhang, Y. J.; Santella, R. M.; Doki, Y.; Cacace, A. M.; Schieren, I. Stable Overexpression of Cyclin D1 in a Human Mammary Epithelial Cell Line Prolongs the S-phase and Inhibits Growth. Oncogene. 1995, 10, 953–961.
   PubMed Web of Science ®Google Scholar
• Alanen, K. A.; Kuopio, T.; Koskinen, P. J.; Nevalainen, T. J. Immunohistochemical Labelling for Prostate Specific Antigen in Nonprostatic Tissues. Path Res. Pract. 1996, 192, 233–237. DOI: 10.1016/S0344-0338(96)80226-3.
   PubMed Web of Science ®Google Scholar
• Narita, D.; Anghel, A.; Motoc, M. Prostate-specific Antigen May Serve as a Pathological Predictor in Breast. Cancer Rom. J. Morphol. Embryol. 2008, 49(2), 173–180.
   PubMed Web of Science ®Google Scholar
• Zarghami, N.; Grass, L.; Diamandis, E. Steroid Hormone Regulation of Prostate-specific Antigen Gene Expression in Breast Cancer. Br. J. Cancer. 1997, 75(4), 579–588. DOI: 10.1038/bjc.1997.101.
   PubMed Web of Science ®Google Scholar
• Tanaka, A.; Kamiakito, T.; Takayashiki, N.; Sakurai, S.; Saoto, K. Fibroblast Growth Factor 8 Expression in Breast Carcinoma: Associations with Androgen Receptor and Prostate Specific Antigen Expressions. Virchows Arch. 2002, 441(4), 380–384. DOI: 10.1007/s00428-002-0687-9.
   PubMed Web of Science ®Google Scholar
• Yang, Q.; Nakamura, M.; Nakamura, Y.; Yoshimura, G.; Suzuma, T.; Umemura, T.; Tamaki, T.; Mori, I.; Sakurai, T.; Kakudo, K. Correlation of Prostate-specific Antigen Promoter Polymorphism with Clinicopathological Characteristics in Breast Cancer. Anticancer Res. 2002, 22(3), 1825–1828.
   PubMed Web of Science ®Google Scholar
• Kidwai, N.; Gong, Y.; Sun, X.; Deshpande, C. G.; Yeldandi, A.; Rao, M.; Badve, S. Expression of Androgen Receptor and Prostate-specific Antigen in Malebreast Carcinoma. Breast Cancer Res. 2004, 6(1), R18–R23. DOI: 10.1186/bcr733.
   PubMed Web of Science ®Google Scholar
• Fortier, A.; Nelson, B.; Grella, D.; Holaday, J. Antiangiogenic Activity of Prostate-specific Antigen. J. Natl. Cancer Inst. 1999, 91(19), 1635–1640. DOI: 10.1093/jnci/91.19.1635.
   PubMedGoogle Scholar
• Lai, L.; Erbas, H.; Lennard, T.; Peaston, R. Prostate-specific Antigen in Breast Cyst Fluid: Possible Role of Prostate-specific Antigen in Hormone-dependent Breast Cancer. Int. J. Cancer. 1996, 66(6), 743–746. DOI: 10.1002/(SICI)1097-0215(19960611)66:6<743::AID-IJC6>3.0.CO;2-#.
   PubMed Web of Science ®Google Scholar
• Miller, M.; Unger, P.; Bleiweiss, I. Immunohistochemical Analysis of Prostate Specific Antigen in Breast Cancer. Breast Cancer Res. Treat. 2001, 68(2), 111–116. DOI: 10.1023/a:1011959127928.
   PubMed Web of Science ®Google Scholar
• Xu, Y.; Chen, S. Y.; Ross, K. N.; Balk, S. P. Androgens Induce Prostate Cancer Cell Proliferation through Mammalian Target of Rapamycin Activation and Post-transcriptional Increases in Cyclin D Proteins. Cancer Res. 2006, 66, 7783–7792. DOI: 10.1158/0008-5472.CAN-05-4472.
   PubMed Web of Science ®Google Scholar